AUS
NZ
UK
CA
USA
IND
Headlines
- Janney Montgomery Scott LLC reduced its holdings in Eastman Chemical by 4.7% in the fourth quarter.
- Insider sales evidenced by substantial share transactions from executives Stephen Glenn Crawford and Christopher Moore Killian.
- Experts provide mixed ratings for Eastman Chemica
Eastman Chemical (NYSE:EMN) has experienced notable changes in investment positions, reflecting strategic financial maneuvers by institutional investors. Janney Montgomery Scott LLC decreased its stake in Eastman Chemical by 4.7% during the fourth quarter, translating to a sale of 996 shares, with the firm now holding 20,081 shares valued at $1,834,000 as per recent SEC filings.
In contrast, other institutional investors have made significant additions to their holdings. Dakota Wealth Management increased its shares by 14.6%, now owning 44,675 shares valued at $4,081,000. New positions were also taken by Kera Capital Partners Inc. and Merit Financial Group LLC, while HB Wealth Management LLC more than doubled its stake. Notably, 83.65% of Eastman Chemical's stock is held by institutional investors, indicating strong market confidence.
Insider activity has been active, with EVP Stephen Glenn Crawford executing a substantial sale of 10,504 shares. The transaction, executed at an average price of $105.00 per share, resulted in a total value of $1,102,920. This action decreased Crawford's position by 18.18%. Similarly, SVP Christopher Moore Killian sold 3,061 shares, translating to a 19.84% reduction in his holdings. Overall, insiders have sold a total of 18,021 shares in the last quarter, equating to around $1,895,948.
Further adding to positive operational metrics, Eastman Chemical recently declared an increased quarterly dividend, enhancing it from $0.81 to $0.83. This follows its financial strategy conducive for long-term investor returns, yielding a 3.34% annual return. Eastman Chemical's key offerings in specialty materials continue to encompass US, China, and international markets, with robust portfolios in additives, solvents, and coalescent products.
The stock's performance, strategic internal sales, institutional investor adjustments, and expert reports provide a comprehensive view of Eastman Chemical's evolving financial landscape.
